Table 1 The explicit numbers of annually approved drugs analyzed in this study, collecting from the official online site of the U.S. FDA

From: Dynamic clinical trial success rates for drugs in the 21st century

Year of approval

FDA CDER

FDA CBER

Drug repurposing

NDA

BLA

BP

All Repo

Pre-2000

ALL

628

200

142

454

145

2023

38

17

16

23

2

2022

22

15

8

31

5

2021

36

14

10

35

4

2020

40

13

5

35

4

2019

38

10

5

28

4

2018

42

17

3

26

3

2017

34

12

9

27

3

2016

14

8

4

18

2

2015

32

13

12

9

3

2014

30

11

10

28

8

2013

25

2

7

20

7

2012

31

8

4

17

6

2011

24

6

4

8

2

2010

14

7

5

12

8

2009

19

6

8

13

7

2008

21

3

5

13

2

2007

17

2

4

19

5

2006

18

4

4

17

11

2005

15

5

5

15

11

2004

30

6

0

20

16

2003

21

6

4

12

11

2002

19

6

3

12

6

2001

24

4

3

10

9

2000

24

5

4

6

6

  1. A total of 828 molecular entities, including 628 new drug applications (NDAs) & 200 biologics license applications (BLAs), approved by FDA Center for Drug Evaluation and Research (FDA CDER) were collected. Moreover, a total of 142 biological products (BPs) approved by the FDA Center for Biologics Evaluation and Research (FDA CBER) were accumulated. The numbers of successful repurposing projects (All Repo) and repositioning count of pre-2000 approved drugs (Pre-2000) were provided.